Section 11 · Monograph
Scopolamine
Reviewed Nov 2026FDA label
Transderm ScopAnticholinergic · patch
- Forms
- Patch: 1.5mg/72h
- Dose
- 1 patch behind ear every 72h
- MOA
- Muscarinic receptor blockade
Indications
- Prevention of nausea and vomiting associated with motion sicknessFDA-labeled
- Prevention of postoperative nausea and vomitingFDA-labeled
Mechanism of Action
- Muscarinic receptor antagonist that suppresses vestibular and central emetic signaling
Full Dosing
Adult / usual
- One 1.5mg patch applied behind the ear at least 4 hours before travel; replace every 72 hours if needed
- Wash hands after handling; do not cut the patch
Contraindications
- Narrow-angle glaucoma
- Known hypersensitivity to scopolamine or belladonna alkaloids
Drug Interactions
- Additive anticholinergic and CNS-depressant effects with other anticholinergics, antihistamines and alcohol
Adverse Effects
- Dry mouth, drowsiness, blurred vision, dilated pupils
- Confusion or hallucinations, especially in older adults
- Urinary retention
- Withdrawal symptoms (nausea, dizziness) after removal
Monitoring Parameters
- Sedation and mental status
- Urinary retention and visual symptoms
Pregnancy & Lactation
- Limited data; use only if benefit justifies risk
- Excreted in milk in small amounts